Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.
| Drug | Target | Relationship | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | Reposition | #cancers |
|---|---|---|---|---|---|---|---|---|---|---|---|
| nabiximols, temozolomide, nabiximols-matched placebo | CYP3A5 | Direct | 1 | ||||||||
| cobicistat | CYP3A5 | Direct | yes | 0 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | SMO | SSL via SMO | 3 | ||||||||
| pembrolizumab, sonidegib | SMO | SSL via SMO | 2 | ||||||||
| alisertib | AURKA | SSL via AURKA | 1 | ||||||||
| alisertib, gemcitabine | AURKA | SSL via AURKA | 1 | ||||||||
| apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib | SMO | SSL via SMO | 1 | ||||||||
| biopsy, biospecimen collection, echocardiography, radionuclide imaging, vismodegib | SMO | SSL via SMO | 1 | ||||||||
| bosutinib | CAMK2G | SSL via CAMK2G | 1 | ||||||||
| diagnostic laboratory biomarker analysis, erlotinib hydrochloride, gemcitabine hydrochloride, vismodegib | SMO | SSL via SMO | 1 | ||||||||
| disulfiram, copper, alkylating agents | GAPDH | SSL via GAPDH | 1 | ||||||||
| disulfiram, copper, alkylating agents | SRSF1 | SSL via SRSF1 | 1 | ||||||||
| enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) | AURKA | SSL via AURKA | 1 | ||||||||
| enzastaurin, lomustine | AURKA | SSL via AURKA | 1 | ||||||||
| enzastaurin, temozolomide, radiation therapy | AURKA | SSL via AURKA | 1 | ||||||||
| gemcitabine hydrochloride, hydrocortisone/placebo, vismodegib | SMO | SSL via SMO | 1 | ||||||||
| gemcitabine, ribociclib, sonidegib, trametinib, filgrastim | SMO | SSL via SMO | 1 | ||||||||
| hyperfractionated radiation therapy, stereotactic radiosurgery, alisertib, quality-of-life assessment | AURKA | SSL via AURKA | 1 | ||||||||
| motixafortide, cemiplimab, gemcitabine, nab paclitaxel | CXCR4 | SSL via CXCR4 | 1 | ||||||||
| pantoprazole, omeprazole | DDAH1 | SSL via DDAH1 | 1 | ||||||||
| plerixafor | CXCR4 | SSL via CXCR4 | yes | 1 | |||||||
| plerixafor, temozolomide, whole-brain radiotherapy (wbrt), radiation therapy | CXCR4 | SSL via CXCR4 | 1 | ||||||||
| porfimer sodium | LDLR | SSL via LDLR | 1 | ||||||||
| porfimer sodium, adjuvant therapy, conventional surgery | LDLR | SSL via LDLR | 1 | ||||||||
| porfimer sodium, endoscopic ultrasonography, photodynamic therapy, gemcitabine hydrochloride | LDLR | SSL via LDLR | 1 | ||||||||
| radiation therapy, temozolomide, plerixafor, laboratory biomarker analysis, pharmacological study | CXCR4 | SSL via CXCR4 | 1 | ||||||||
| vismodegib, sirolimus, positron emission tomography, computed tomography, pharmacological study, laboratory biomarker analysis, fludeoxyglucose f 18 | SMO | SSL via SMO | 1 | ||||||||
| vismodegib, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study | SMO | SSL via SMO | 1 | ||||||||
| amifampridine | KCNQ4 | SSL via KCNQ4 | yes | 0 | |||||||
| amifampridine phosphate | KCNQ4 | SSL via KCNQ4 | yes | 0 | |||||||
| dalfampridine | KCNQ4 | SSL via KCNQ4 | yes | 0 | |||||||
| ezogabine | KCNQ4 | SSL via KCNQ4 | yes | 0 | |||||||
| fingolimod | S1PR2 | SSL via S1PR2 | yes | 0 | |||||||
| fingolimod hydrochloride | S1PR2 | SSL via S1PR2 | yes | 0 | |||||||
| glasdegib | SMO | SSL via SMO | yes | 0 | |||||||
| glasdegib maleate | SMO | SSL via SMO | yes | 0 | |||||||
| guanidine | KCNQ4 | SSL via KCNQ4 | yes | 0 | |||||||
| guanidine hydrochloride | KCNQ4 | SSL via KCNQ4 | yes | 0 | |||||||
| pentoxifylline | PDE6H | SSL via PDE6H | yes | 0 | |||||||
| phenindione | GGCX | SSL via GGCX | yes | 0 | |||||||
| sonidegib | SMO | SSL via SMO | yes | 0 | |||||||
| sonidegib phosphate | SMO | SSL via SMO | yes | 0 | |||||||
| vismodegib | SMO | SSL via SMO | yes | 0 |